Axial: https://linktr.ee/axialxyz
Axial partners with great founders and inventors. We invest in early-stage life sciences companies such as Appia Bio, Seranova Bio, Delix Therapeutics, Simcha Therapeutics, among others often when they are no more than an idea. We are fanatical about helping the rare inventor who is compelled to build their own enduring business. If you or someone you know has a great idea or company in life sciences, Axial would be excited to get to know you and possibly invest in your vision and company . We are excited to be in business with you - email us at info@axialvc.com
Ablynx pioneered nanobodies, got acquired for €3.9B by Sanofi in 2018, and might have massively undersold itself. Founded in 2001 based on research out of Brussels, the company can trace its origins back to a Moroccan camel in the 1990s to a drug approval in 2019.
Nanobodies = single-domain antibody fragments, combining the advantages of conventional antibodies with some features of small molecules. They were initially found in camels and llamas & are significantly smaller than human antibodies https://originofimpact.sites.vib.be/en/nanobodies
Ablynx built a near technology monopoly with 100s of patents & even owning the nanobody trademark. Their lead asset, caplacizumab, an anti-von Willebrand factor nanobody, treating aTTP was approved in 2019 targeting $100Ms in peak sales. Setting up a decade of new nanobody trials.
In retrospective, depending on the success of caplacizumab and other drug candidates, Ablynx might have sold itself too early. Learn more about Ablynx and their platform here: https://www.sanofi.com/en/science-and-innovation/research-and-development/technology-platforms/nanobody-technology-platform